Marathon Capital Management Trims Holdings in Johnson & Johnson $JNJ

Marathon Capital Management trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 8.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 26,186 shares of the company’s stock after selling 2,550 shares during the period. Johnson & Johnson comprises 1.2% of Marathon Capital Management’s investment portfolio, making the stock its 29th biggest holding. Marathon Capital Management’s holdings in Johnson & Johnson were worth $5,419,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in JNJ. Brighton Jones LLC raised its stake in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares during the period. United Bank raised its stake in shares of Johnson & Johnson by 110.7% in the 1st quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after acquiring an additional 4,876 shares during the period. Sivia Capital Partners LLC raised its stake in shares of Johnson & Johnson by 13.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock valued at $896,000 after acquiring an additional 692 shares during the period. Wealth Group Ltd. raised its stake in shares of Johnson & Johnson by 12.8% in the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock valued at $226,000 after acquiring an additional 168 shares during the period. Finally, Schnieders Capital Management LLC. raised its stake in shares of Johnson & Johnson by 9.8% in the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock valued at $11,255,000 after acquiring an additional 6,584 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA grants Priority Review for IMAAVY (nipocalimab-aahu), accelerating a potential new approval path for treatment of warm autoimmune hemolytic anemia (wAIHA). Priority Review shortens review time and raises the odds of earlier revenue contribution from this biologic if approved. FDA grants Priority Review for IMAAVY
• Positive Sentiment: JNJ agreed to acquire Atraverse Medical to expand its cardiac ablation and left?heart access portfolio — a tuck?in deal that strengthens the cardiovascular offering in MedTech and supports longer-term growth in a high?value procedure set. Johnson & Johnson Enters into a Definitive Agreement to Acquire Atraverse Medical
• Positive Sentiment: Company commentary and analyst notes point to MedTech improvement in Q1 and a better 2026 outlook for devices — supportive for near?term revenue momentum given MedTech is ~36% of sales. J&J Sees Continued MedTech Improvement in Q1
• Positive Sentiment: Management says AI is cutting lead?generation time for drug discovery roughly in half — a productivity gain that could speed R&D efficiency and reduce time/cost to identify candidates over time. J&J Sees AI Halving the Time to Generate Drug Development Leads
• Neutral Sentiment: JNJ will present at Bernstein’s Strategic Decisions Conference (May 27) — a routine investor event that gives management a forum to update guidance and strategy; could move the stock if new detail or guidance is provided. Johnson & Johnson to Participate in Bernstein’s Conference
• Neutral Sentiment: Articles highlighting JNJ as a dividend aristocrat and inclusion on “quality dividend” lists reinforce income investor interest, supporting demand from yield-focused holders but with limited incremental price impact. JNJ Among the 10 Best Quality Dividend Stocks to Buy According to Reddit
• Negative Sentiment: Report that J&J plans to sell prescription drugs via TrumpRx as part of a cost?reduction push could concern investors about pricing strategies, margin pressure, and reputational/PR risk if perceived as discounting core products. Johnson & Johnson Plans to Sell Prescription Drugs to TrumpRx

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 22,623 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the transaction, the executive vice president owned 26,769 shares in the company, valued at approximately $6,540,469.77. This represents a 45.80% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 30,142 shares of company stock valued at $7,360,528 in the last quarter. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Up 1.0%

NYSE JNJ opened at $227.67 on Wednesday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 52 week low of $146.12 and a 52 week high of $251.71. The stock has a market capitalization of $548.05 billion, a PE ratio of 26.32, a price-to-earnings-growth ratio of 2.21 and a beta of 0.34. The firm has a 50 day moving average of $239.51 and a two-hundred day moving average of $219.37.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. During the same quarter in the previous year, the firm posted $2.77 earnings per share. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, research analysts expect that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be issued a dividend of $1.34 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date is Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.4%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.12%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on JNJ shares. HSBC lifted their price objective on shares of Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a report on Wednesday, April 15th. Stifel Nicolaus lifted their price objective on shares of Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, April 15th. Raymond James Financial lifted their price objective on shares of Johnson & Johnson from $237.00 to $258.00 and gave the company an “outperform” rating in a report on Wednesday, April 15th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Eighteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $252.48.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.